Ontada Research Highlights Power of Real-World Oncology Data at ISPOR 2022

Studies Show the Ability of Real-World Oncology Evidence to Generate Insights into Treatment Effectiveness and Patient Outcomes

IRVING, Texas–(BUSINESS WIRE)–Ontada®, a McKesson business focused on provider technology and actionable real-world research, education and evidence in oncology, announced the acceptance of seven abstracts for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The leading global conference for health economics and outcomes research, ISPOR 2022 will take place in Washington, D.C., and virtually from May 15-18, 2022.

“The acceptance of these studies showcases the critical role Ontada’s real-world data and evidence solutions play in our life science partners’ ability to accelerate the development and commercialization of oncology therapies,” said Susan Shiff, Ph.D., president of Ontada. “The studies highlight a wide range of innovative ways to gain insight into treatment patterns and outcomes. These are critical to support drug development and the advancements of new medicines designed to improve patient care.”

In an oral abstract session on Tuesday, May 17 from 4:30 to 5:30pm ET, results will be presented from the study, “Feasibility of Using Oncology Specific Electronic Health Records (EHR) Data to Emulate Clinical Trial Inclusion and Exclusion Criteria.” Assessing the utility of both structured and unstructured data from oncology-specific EHR systems, the study examined eligibility criteria of oncology clinical trials to assess the degree to which real-world data can be used to retrospectively replicate the information needed in trials.

“These results demonstrate that oncology-specific EHR data can be leveraged to emulate inclusion and exclusion criteria of clinical trials, which offers the ability to evaluate treatment options using external controls in cases where a randomized clinical trial may not be feasible,” said Nicholas Robert, M.D., study co-author and chief medical officer of Ontada. “Complementing clinical trials by capturing data on the effectiveness of drugs with real-world evidence will ultimately improve our understanding of how drugs perform in broader patient groups.”

Ontada’s data scientists and researchers leveraged our real-world data and analytics capabilities in additional poster studies to be presented at this year’s ISPOR:

• A Proposed Framework for Evaluating Continuity of Data Coverage in Electronic Health Record and Administrative Claims Data in Real-World Evidence (RWE) Studies

• Application of Medication History for Comorbidity Assessment in Cancer Patients

• HER2 and Other Biomarker Testing Patterns Among Patients with Advanced Gastric Cancer (GC) or Gastric Esophageal Junction Cancer (GEJC)

• Lack of Standardization in Quantitative Evaluations of the Efficacy-Effectiveness Gap (EEG) for Cancer Therapies: A Targeted Literature Review (TLR)

• Frequency of and Testing Patterns for Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) Among Solid Tumors in a US Community Oncology Setting

• Integrating Data from Disparate Sources to Create a Comprehensive Patient Journey: A Case Study in Prostate Cancer

The full schedule of presentations, including timing and author information, can be found here. For more information or to interview a trial investigator, contact Ryan Mathre at 651.335.2338 or [email protected].

About Ontada

Ontada® is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer. Part of McKesson Corporation, we support science through our data, technology and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit ontada.com or follow @OntadaOncology.

Contacts

General and Business Press

Ontada

Ryan Mathre, External Communications

651.335.2338 [email protected]